Fig. 2.

Identification of the DHODH inhibitor 10580 as a new anti-GIC compound.

(A) Chemical structures of 10607, 10580, and traditional DHODH inhibitors. (B) Dose-dependent effects of the candidate compounds, 10607 (open circle), 9700 (open triangle), and 10580 (closed circle) against GICs (E6 and E16 cells) and GICRs (E6R and E16R cells). (C) Dose-dependent effects of the DHODH inhibitors teriflunomide (open circle), leflunomide (open square), vidofludimus (cross), BRQ (open diamond), and 10580 (closed triangle) against GICs (E6 and E16 cells). (D) Pyrimidine biosynthesis pathways. (E) Representative data of metabolites in control (DMSO, white column) and 10580-treated (black column) GICs (E6 and E16 cells). All experiments were repeated at least 3 times with similar results. Error bar: ±SD. Statistical significance was determined by the t-test. *P < 0.05, **P < 0.01, ***P < 0.001.